Two-tiered hypotheses for Duchenne muscular dystrophy

Cellular and Molecular Life Sciences

Volumn 65, Issue 11, 2008, Pages 1621-1625

  Grounds, M D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Fibrosis; Growth; Impact of age; Muscular dystrophy; Myofibre necrosis; Therapy

Indexed keywords

ANTIBODY; CORTICOSTEROID; CREATINE KINASE; CROMOGLYCATE DISODIUM; CV1Q ANTIBODY; DYSTROPHIN; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL FEATURE; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EXERCISE; FIBROSIS; GENE THERAPY; GENETIC DISORDER; HUMAN; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; NONHUMAN; NUTRITIONAL SUPPORT; SHORT SURVEY; SKELETAL MUSCLE; SPORTS MEDICINE; STEM CELL TRANSPLANTATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DIET THERAPY; DYSTROPHIN; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 44749094724     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-7574-8     Document Type: Short Survey

References (15)

1. Emery, E. H. (2002) The muscular dystrophies. Lancet 359, 687-695.
2. Grounds, M. D. (2008) Complexity of extracellular matrix and skeletal muscle regeneration. In: Skeletal Muscle Repair and Regeneration, pp. 269-302, Schiaffino, S. and Partridge, T. A. (eds.), Springer, New York.
3. Alexakis, C., Partridge, T. and Bou-Gharios, G. (2007) Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am. J. Physiol. Cell Physiol. 293, C661-669.
4. Radley, H. G., Davies, M. D. and Grounds, M. D. (2008) Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul. Disord. Jan 18 [Epub ahead of print]
5. Radley, H. G. and Grounds, M. D. (2006) Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol. Dis. 23, 387-397.
6. Peault, B., Rudnicki, M., Torrente, Y., Cossu, G., Tremblay, J. P., Partridge, T., Gussoni, E., Kunkel, L. M. and Huard, J. (2007) Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther. 15, 867-877.
7. Davies, K. E. and Grounds, M.D. (2007) Modified patient stem cells as prelude to autologous treatment of Muscular Dystrophy. Cell Stem Cell 1, 595-596.
8. Odom, G. L., Gregorevic, P. and Chamberlain, J. S. (2007) Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim. Biophys. Acta 1772, 243-262.
9. Muntoni, F. and Wells, D. (2007) Genetic treatments in muscular dystrophies. Curr. Opin. Neurol. 20, 590-594.
10. Yokota, T., Pistilli, E., Duddy, W. and Nagaraju, K. (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin. Biol. Ther. 7, 831-842.
11. Angelini, C. (2007) The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 36, 424-435.
12. Tidball, J. G. and Wehling-Henricks, M. (2004) Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr. Res. 56, 831-841.
13. Whitehead, N. P., Yeung, E. W. and Allen, D. G. (2006) Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 33, 657-662.
14. Radley, H. G., De Luca, A., Lynch, G. S. and Grounds, M. D. (2007) Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int. J. Biochem. Cell Biol. 39, 469-477.
15. Lanfear, D. E. and McLeod, H. L. (2007) Pharmacogenetics: using DNA to optimize drug therapy. Am. Fam. Physician. 76, 1179-1182.